Pinealon

Pinealon (EDR) is a synthetic tripeptide composed of glutamic acid, aspartic acid, and arginine (Glu-Asp-Arg). It belongs to the Khavinson peptide bioregulator family, developed at the Saint Petersburg Institute of Bioregulation and Gerontology. Pinealon was isolated from the polypeptide neuroprotective drug Cortexin and is designed to target central nervous system function.

Pinealon's mechanism involves epigenetic regulation of gene expression in neural tissue. Studies show it can penetrate cell membranes and interact with DNA, influencing the expression of genes related to neuronal survival, synapse formation, and circadian rhythm regulation. The peptide has demonstrated the ability to interfere with the elimination of dendritic spines in neuronal cultures, potentially preserving synaptic connectivity. Its small size (molecular weight ~390 Da) allows it to readily cross the blood-brain barrier.

Research has demonstrated neuroprotective effects in models of Alzheimer's and Huntington's disease, where Pinealon preserved dendritic spine density. Studies show improvements in memory formation and cognitive function in aged animal models. The peptide also influences pineal gland function and melatonin production, supporting circadian rhythm regulation and sleep quality. Its favorable safety profile and oral bioavailability distinguish it from many other neuropeptides. Pinealon is studied both as a standalone compound and in combination with other nootropic peptides such as Selank and PE-22-28 for synergistic cognitive enhancement.